STOCK TITAN

RevBio Issued a Key Patent for its Regenerative Bone Adhesive Technology by the United States Patent and Trademark Office

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

RevBio has been granted its 10th U.S. patent (12,178,937) for the TETRANITE® bone adhesive technology, expanding protection for injectable mineral-organic structural bone adhesive compositions containing alpha tricalcium phosphate. This complements their existing patent 11,638,777 for bone fracture repair methods.

TETRANITE® is notable as the only patented bone adhesive containing phosphoserine, an organic compound linked to bone regeneration. RevBio acquired exclusive worldwide patent rights from Stryker (NYSE: SYK) for six patent families, providing protection through 2033. Since 2016, RevBio has filed fourteen Patent Cooperation Treaty applications, with protection extending to 2043 across multiple jurisdictions including the U.S., EU, Canada, Australia, Japan, and China.

RevBio ha ottenuto il suo 10° brevetto statunitense (12,178,937) per la tecnologia dell'adesivo osseo TETRANITE®, ampliando la protezione per le composizioni adesive ossee mineral-organiche iniettabili contenenti fosfato di tricalcio alfa. Questo complementa il loro brevetto esistente 11,638,777 per i metodi di riparazione delle fratture ossee.

TETRANITE® è particolare poiché è l'unico adesivo osseo brevettato contenente fosfoserina, un composto organico legato alla rigenerazione ossea. RevBio ha acquisito diritti di brevetto esclusivi a livello mondiale da Stryker (NYSE: SYK) per sei famiglie di brevetti, garantendo protezione fino al 2033. Dal 2016, RevBio ha presentato quattordici domande di brevetto ai sensi del Trattato di Cooperazione in materia di Brevetti, con protezione estesa fino al 2043 in diverse giurisdizioni tra cui Stati Uniti, UE, Canada, Australia, Giappone e Cina.

RevBio ha recibido su décima patente estadounidense (12,178,937) para la tecnología del adhesivo óseo TETRANITE®, ampliando la protección para las composiciones adhesivas óseas mineral-orgánicas inyectables que contienen fosfato de tricalcio alfa. Esto complementa su patente existente 11,638,777 para métodos de reparación de fracturas óseas.

TETRANITE® es notable ya que es el único adhesivo óseo patentado que contiene fosfoserina, un compuesto orgánico vinculado a la regeneración ósea. RevBio adquirió derechos de patente exclusivas a nivel mundial de Stryker (NYSE: SYK) para seis familias de patentes, brindando protección hasta 2033. Desde 2016, RevBio ha presentado catorce solicitudes de Tratado de Cooperación en Materia de Patentes, con protección que se extiende hasta 2043 en múltiples jurisdicciones, incluyendo EE. UU., UE, Canadá, Australia, Japón y China.

RevBioTETRANITE® 뼈 접착제 기술에 대한 미국 특허 제10호(12,178,937)를 취득하여 알파 삼인산칼슘을 함유한 주입 가능한 미네랄-유기 구조 뼈 접착제 조성물에 대한 보호를 확장했습니다. 이는 뼈 골절 수리 방법에 대한 기존 특허 11,638,777을 보완합니다.

TETRANITE®는 뼈 재생과 관련된 유기 화합물인 포스포세린을 포함하는 유일한 특허 뼈 접착제로 주목받고 있습니다. RevBio는 Stryker (NYSE: SYK)로부터 여섯 개의 특허 군에 대한 독점 전세계 특허 권리를 획득하여 2033년까지 보호를 제공합니다. 2016년 이후 RevBio는 14건의 특허 협력 조약 신청을 제출했으며, 미국, EU, 캐나다, 호주, 일본 및 중국을 포함한 여러 관할권에서 2043년까지 보호가 확장되고 있습니다.

RevBio a obtenu son 10ème brevet américain (12,178,937) pour la technologie d'adhésif osseux TETRANITE®, élargissant la protection pour les compositions d'adhésifs osseux structurels minéraux-organiques injectables contenant du phosphate tricalcique alpha. Ceci complète leur brevet existant 11,638,777 pour les méthodes de réparation des fractures osseuses.

TETRANITE® est notable en tant que seul adhésif osseux breveté contenant de la phosphosérine, un composé organique lié à la régénération osseuse. RevBio a acquis des droits de brevet exclusifs à l'échelle mondiale auprès de Stryker (NYSE: SYK) pour six familles de brevets, garantissant une protection jusqu'en 2033. Depuis 2016, RevBio a déposé quatorze demandes de brevet dans le cadre du Traité de coopération en matière de brevets, avec une protection s'étendant jusqu'en 2043 dans plusieurs juridictions, notamment les États-Unis, l'UE, le Canada, l'Australie, le Japon et la Chine.

RevBio hat sein 10. US-Patent (12,178,937) für die TETRANITE® Knochenkleber-Technologie erhalten und die Schutzrechte für injizierbare mineralisch-organische strukturelle Knochenklebezusammensetzungen mit Alpha-Trikalziumphosphat erweitert. Dies ergänzt das bestehende Patent 11,638,777 für Methoden zur Reparatur von Knochenfrakturen.

TETRANITE® ist bemerkenswert, da es der einzige patentierte Knochenkleber ist, der Phosphoserin enthält, eine organische Verbindung, die mit der Knochenregeneration in Verbindung steht. RevBio hat sich die exklusiven weltweiten Patentrechte von Stryker (NYSE: SYK) für sechs Patentfamilien gesichert, die bis 2033 Schutz bieten. Seit 2016 hat RevBio vierzehn Anträge nach dem Patentzusammenarbeitsvertrag eingereicht, wobei der Schutz bis 2043 in mehreren Gerichtsbarkeiten, einschließlich der USA, der EU, Kanada, Australien, Japan und China, erweitert wird.

Positive
  • Secured 10th U.S. patent strengthening intellectual property portfolio
  • Exclusive worldwide patent license from Stryker
  • Patent protection extends through 2043
  • Global patent coverage across major markets
Negative
  • None.

Insights

This patent issuance represents a significant strategic development in the orthopedic biomaterials sector, particularly for Stryker , which maintains licensing rights to RevBio's TETRANITE technology. The expanded patent protection for injectable mineral-organic bone adhesives incorporating alpha tricalcium phosphate strengthens the commercial potential of this platform technology.

The technical breakthrough lies in the unique combination of phosphoserine with mineral components, creating a biomaterial that offers three critical advantages:

  • Superior adhesive properties for immediate fixation
  • Weight-bearing strength for structural support
  • Biocompatibility promoting natural bone regeneration

From a market perspective, this patent fortification has dual significance. For Stryker, it enhances their exclusive position in the bone adhesive market segment through 2033, complementing their existing orthopedic portfolio. The extended protection through 2043 for newer applications provides a substantial runway for product development and commercialization.

The global patent strategy, targeting key markets like the EU, Japan and China, indicates the technology's commercial potential in the $8.5 billion orthopedic biomaterials market. The inclusion of phosphoserine as a bone regeneration promoter differentiates TETRANITE from conventional bone cements, potentially commanding premium pricing and faster market adoption.

However, success will ultimately depend on clinical validation and regulatory approvals. The technology's ability to demonstrate superior outcomes in ongoing trials and secure FDA clearance will be important milestones for market realization.

The Issuance of this 10th Patent for TETRANITE® Significantly Expands RevBio’s Patent Protection for its Novel Structural Bio Adhesive Technology Platform

LOWELL, Mass.--(BUSINESS WIRE)-- The United States Patent and Trademark Office recently issued patent 12,178,937 entitled “Compositions and Methods for Adhesion to Surfaces,” which constitutes the 10th U.S. patent that covers the TETRANITE bone adhesive technology. This patent expands the protected technology to include injectable mineral-organic structural bone adhesive compositions that comprise alpha tricalcium phosphate. The issuance of this patent complements RevBio’s existing U.S. patent 11,638,777, which covers the method of repairing fractured bone using the aforementioned adhesive composition. These recently issued patents enlarge RevBio’s portfolio of adhesive compositions for bone repair. The novel TETRANITE biomaterial is also the only patented bone adhesive to include phosphoserine, an organic compound, which has been shown in published literature to play a role in the process of bone regeneration.

Patent 12,178,937 shows additional adhesive compositions that may include alpha tricalcium phosphate are now covered as part of this patent-protected injectable adhesive technology. The novel TETRANITE™ biomaterial is also the only patented bone adhesive to include phosphoserine which has been shown in published literature to play a role in the bone regeneration process. (Graphic: Business Wire)

Patent 12,178,937 shows additional adhesive compositions that may include alpha tricalcium phosphate are now covered as part of this patent-protected injectable adhesive technology. The novel TETRANITE™ biomaterial is also the only patented bone adhesive to include phosphoserine which has been shown in published literature to play a role in the bone regeneration process. (Graphic: Business Wire)

"The granting of this patent continues to expand RevBio's controlling intellectual property estate in the mineral-organic bone adhesive space. This novel and very promising biomaterial distinctively combines excellent handling characteristics, weight-bearing strength, and high biocompatibility with unique adhesive and bone regenerative properties," said George Kay, DMD, Chief Scientific Officer and co-founder of RevBio, Inc.

RevBio (formerly known as LaunchPad Medical) obtained an exclusive worldwide patent license from Stryker Corporation (NYSE: SYK) to six patent families which cover the bone adhesive technology composition and specific methods for its use. These issued patent families provide patent protection through 2033, resulting in a lengthy period of protection for RevBio to develop and market TETRANITE-based products.

Since 2016, RevBio has filed fourteen Patent Cooperation Treaty (PTC) patent applications to protect and expand its robust and growing patent portfolio for which many of these patents will provide protection of its bone adhesive platform through the year 2043. Four of these applications have issued as U.S. patents while the majority of these applications have published and are at various stages of prosecution in such countries and jurisdictions as the United States, multiple European Union countries, Canada, Australia, Japan, and China. These patent families provide patent coverage for RevBio’s product pipeline, such as compositions including derivatives to the original TETRANITE bone adhesive, expanded methods of use, ancillary devices, and key packaging components.

“As a clinical stage company, it is exciting to receive this key patent that expands patent protection for the full spectrum of indications we are pursuing,” said Brian Hess, CEO and founder of RevBio, Inc. “This new patent will enhance the company’s core value and competitive advantage for our investors who are funding the development of this game-changing technology platform.”

About RevBio, Inc.

RevBio, Inc., is a clinical stage medical device company engaged in the development and commercialization of TETRANITE®, a patented, synthetic, injectable, self-setting, and osteoconductive bone adhesive biomaterial. The company is initially developing this technology for use in the dental, cranial, and broader orthopaedic markets as well as applications in the animal health market. RevBio's Tetranite technology is not yet approved for commercial use.

Michael Tiedemann

mtiedemann@revbio.com

Source: RevBio, Inc.

FAQ

What is the significance of RevBio's new TETRANITE® patent (12,178,937)?

The patent expands protection for RevBio's injectable mineral-organic structural bone adhesive compositions containing alpha tricalcium phosphate, strengthening their intellectual property portfolio in bone adhesive technology.

How long does RevBio's patent protection for TETRANITE® technology extend?

The patent protection extends through 2043, with the original Stryker-licensed patents providing coverage through 2033.

What makes TETRANITE® unique in the bone adhesive market?

TETRANITE® is the only patented bone adhesive containing phosphoserine, an organic compound proven to aid in bone regeneration.

What is the relationship between RevBio and Stryker (SYK)?

RevBio has obtained an exclusive worldwide patent license from Stryker for six patent families covering the bone adhesive technology composition and specific methods for its use.

In which countries does RevBio have patent protection for TETRANITE®?

RevBio has patent coverage in the United States, European Union countries, Canada, Australia, Japan, and China.

Stryker Corporation

NYSE:SYK

SYK Rankings

SYK Latest News

SYK Stock Data

149.22B
360.31M
5.38%
80.38%
1.23%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
PORTAGE